Dr. Ranji Bindra explains the delicate balance that must go into treating the parents of patients in pediatric oncology.
Ranjit Bindra, MD, PhD, from Smilow Cancer Hospital at Yale explains the importance of communicating honestly and sensitively with parents when treating pediatric patients.
In pediatric oncology, nurses have to treat both the patient and the family. This requires a delicate balance that allows the parents to be hopeful and engaged, but realistic. Bindra highlights the importance of revising communication in relation to the patient's status.
FDA Approves Inotuzumab Ozogamicin for Pediatric Patients With ALL
March 6th 2024The antibody-drug conjugate inotuzumab ozogamicin was approved by the FDA for the treatment of patients aged 1 year and older with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia.
FDA Approves Eflornithine for Children, Adults With High-Risk Neuroblastoma
December 14th 2023Eflornithine (Iwilfin) received FDA approval to reduce the risk for relapse in pediatric and adult patients with high-risk neuroblastoma, making it the first therapy to reduce risk for relapse in children with the disease.
FDA Approves Inotuzumab Ozogamicin for Pediatric Patients With ALL
March 6th 2024The antibody-drug conjugate inotuzumab ozogamicin was approved by the FDA for the treatment of patients aged 1 year and older with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia.
FDA Approves Eflornithine for Children, Adults With High-Risk Neuroblastoma
December 14th 2023Eflornithine (Iwilfin) received FDA approval to reduce the risk for relapse in pediatric and adult patients with high-risk neuroblastoma, making it the first therapy to reduce risk for relapse in children with the disease.
Frontline Durvalumab Regimen Improves PFS, Responses in Advanced Endometrial Cancer
Pembrolizumab Plus Chemo Provides Overall Survival Benefit in Endometrial Cancer
Dostarlimab Plus Chemo Demonstrates 31% OS Improvement in Advanced Endometrial Cancer
Olaparib Plus Cediranib May Not Provide Survival Benefit in Platinum-Resistant or Refractory Ovarian Cancer
2 Commerce Drive
Cranbury, NJ 08512